Stephanie E Baldeweg1,2, Mark Vanderpump3, Will Drake4, Narendra Reddy5, Andrew Markey6, Gordon T Plant7,2, Michael Powell2, Saurabh Sinha8, John Wass9. 1. Department of EndocrinologyUniversity College Hospital, London, UK stephanie.baldeweg@uclh.nhs.uk. 2. National Hospital for Neurology and NeurosurgeryLondon, UK. 3. Physicians' ClinicLondon, UK. 4. Department of EndocrinologySt Bartholomew's Hospital, London, UK. 5. Endocrinology/General MedicineUniversity Hospitals Coventry and Warwickshire NHS Trust, University of Warwick, Coventry, UK. 6. The Lister HospitalLondon, UK. 7. Department of EndocrinologyUniversity College Hospital, London, UK. 8. Royal Hallamshire HospitalSheffield, UK. 9. Department of EndocrinologyOxford Centre for Diabetes Endocrinology and Metabolism, The Churchill, Oxford University, Oxford, UK.
Classical pituitary apoplexy is a medical emergency and rapid replacement with
hydrocortisone may be lifesaving. It is caused by haemorrhage and/or infarction of a
tumour within the pituitary gland. A high index of clinical suspicion is essential to
diagnose this condition as prompt management may be life and vision saving. This
guideline aims to take the non-specialist through the initial phase of assessment and
management.The diagnosis of pituitary apoplexy is often delayed as ~80% of these patients will
have no previous history of a pituitary problem and the clinical features mimic other
more common neurological conditions.A diagnosis of pituitary apoplexy should be considered in all patients who have
acute severe headache and any of the following:patients in whom subarachnoid haemorrhage (SAH) and meningitis have been
excludedpatients with neuro-ophthalmic signspatients with pre-existing pituitary tumoursAcute severe headache is the most common and earliest manifestation. Headache may
be accompanied by nausea and vomitingOcular palsies, most commonly a third nerve palsy, can occur due to involvement of
the cavernous sinusReduced visual acuity and visual field defects, most commonly a bi-temporal
hemianopia, are due to optic chiasmal compressionFever, neck stiffness, photophobia or reduced consciousness (similar to
signs/symptoms of SAH or meningitis) may occur
Precipitating factors
Hypertension, major surgery, especially coronary artery bypass grafting, dynamic testing
of the pituitary gland, anticoagulation therapy, coagulopathies, pregnancy and head
trauma.SAH due to ruptured intracranial aneurysm or arteriovenous malformationBacterial/viral meningitisBrainstem infarctionCavernous sinus thrombosisEnsure haemodynamic stability through supportive measuresUrgent bloods: urea and electrolytes, full blood count, renal and liver function
tests, clotting profileIndications for empirical steroid therapy in patients with pituitary apoplexy are
haemodynamic instability, altered consciousness level, reduced visual acuity and
severe visual field defects. Steroid replacement is potentially lifesaving in
these patientsIn adults, hydrocortisone 100 mg i.m. bolus followed by
50–100 mg six hourly by intramuscular injection or
100–200 mg as an intravenous bolus followed by 2–4 mg
per hour by continuous i.v. infusion can be usedCareful assessment of fluid and electrolyte balanceIdeally, endocrine evaluation with blood samples for random serum cortisol, TSH,
free T4, prolactin, IGF1, LH, FSH, testosterone (men), oestradiol
(women) for later analysisBedside assessment of visual acuity and fieldsFurther neuro-ophthalmic assessments can be undertaken when the patient is
clinically stableCT brain (± LP) to exclude SAH and meningitis should be undertaken if not
already doneMagnetic resonance imaging (MRI) is the investigation of choice and has been shown
to confirm the diagnosis in over 90% of patients. A pituitary CT is indicated if
MRI is contraindicated or not possibleUrgent referral to the joint neurosurgical/endocrine unit for definitive
management
After emergency care: where should patients with pituitary apoplexy be
managed?
Once the diagnosis has been confirmed, it is recommended that all patients be
transferred once medically stabilised, following liaison and advice from the specialist
neurosurgical/endocrine team, to the local neurosurgical/endocrine team as soon as
possible. Neurosurgical high dependency unit (HDU) facilities must be available. This
team must have access to specialist endocrine and ophthalmological expertise. These
patients should then be managed according the Society for Endocrinology UK guidelines
for the management of pituitary apoplexy (1).
Indications for surgery
Patients should first be stabilised medically with steroid replacement, if needed,
before surgical intervention. Studies have shown significantly greater improvement in
visual acuity and visual field defects in patients who had early surgery (within
8 days).Surgical intervention should be considered in patients with:Severely reduced visual acuitySevere and persistent visual field defectsDeteriorating level of consciousness
Long-term follow-up
All patients with pituitary apoplexy need follow-up by endocrine and neurosurgical
teams. They require repeat assessment of pituitary and visual function, at
4–6 weeks. Thereafter, 6–12 monthly follow-up to optimise
hormonal replacement and to monitor tumour progression/recurrence.
Summary
See Fig. 1 for an emergency management summary.
Figure 1
Pituitary apoplexy emergency management summary.
Pituitary apoplexy emergency management summary.Pituitary apoplexy is a rare and potentially lethal endocrine emergency, characterised
by acute severe headache, visual defects, and/or reduced consciousness.The clinical presentation often mimics other more common neurological emergencies.Prompt resuscitation and corticosteroid replacement may be lifesaving.MRI scan is the investigation of choice.Urgent discussion with the regional neurosurgical/endocrine team is essential.Surgical intervention should be considered in patients with severe and persisting visual
defects or in those with deteriorating level of consciousness after medical
stabilisation and steroid replacement.
Authors: Senthil Rajasekaran; Mark Vanderpump; Stephanie Baldeweg; Will Drake; Narendra Reddy; Marian Lanyon; Andrew Markey; Gordon Plant; Michael Powell; Saurabh Sinha; John Wass Journal: Clin Endocrinol (Oxf) Date: 2011-01 Impact factor: 3.478
Authors: Patrick D Kelly; Shanik J Fernando; Jordan A Malenke; Rakesh K Chandra; Justin H Turner; Lola B Chambless Journal: J Neurol Surg B Skull Base Date: 2020-01-24
Authors: Ali Abbara; Sophie Clarke; Pei Chia Eng; James Milburn; Devavrata Joshi; Alexander N Comninos; Rozana Ramli; Amrish Mehta; Brynmor Jones; Florian Wernig; Ramesh Nair; Nigel Mendoza; Amir H Sam; Emma Hatfield; Karim Meeran; Waljit Singh Dhillo; Niamh M Martin Journal: Endocr Connect Date: 2018-08-23 Impact factor: 3.335